{
  "1696.HK": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "HKD",
    "exchange": "HKG",
    "industry": "Medical Devices",
    "long_name": "Sisram Medical Ltd",
    "market": "hk_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SISRAM MED",
    "state": null,
    "summary": "Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers a portfolio of treatment systems for non-invasive medical aesthetic treatments, including hair removal, skin rejuvenation, skin resurfacing, vascular and pigmented lesions treatment, body contouring, skin tightening, tattoo removal, acne treatment, and cellulite reduction; and minimally invasive treatments, such as minimally invasive treatments, such as laser assisted liposuction and fat grafting, and feminine health, as well as treatment of varicose veins and ear, nose, and throat procedures. The company also provides beauty product line treatment systems, such as Rejuve and Spadeep; and manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, ClearLift, Accent, BeautiFill, and FemiLift brands. The company sells its products directly to treatment providers and treatment recipients; and through distributors and direct sales. Sisram Medical Ltd was incorporated in 2013 and is headquartered in Caesarea, Israel.",
    "website": "http://www.sisram-medical.com",
    "zipcode": "38900"
  },
  "1BT.F": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Enlivex Therapeutics Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ENLIVEX THERAP.LTD.IS-,01",
    "state": null,
    "summary": "Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",
    "website": "http://www.enlivex.com",
    "zipcode": "7403618"
  },
  "2F5.F": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BiondVax Pharmaceuticals Ltd.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOND.PHAR.S.ADS/40 IL-01",
    "state": null,
    "summary": "BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.",
    "website": "http://www.biondvax.com",
    "zipcode": "7414002"
  },
  "2QM.SG": {
    "city": "Omer",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Medical Devices",
    "long_name": "Medigus Ltd.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Medigus Ltd. Reg.Shares(Spon.AD",
    "state": null,
    "summary": "Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel.",
    "website": "http://www.medigus.com",
    "zipcode": "8496500"
  },
  "2RH.F": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "RedHill Biopharma Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "REDHILL B.S.ADR 10/IL-,01",
    "state": null,
    "summary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.redhillbio.com",
    "zipcode": "6473921"
  },
  "2RW.F": {
    "city": "Yokneam Illit",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "ReWalk Robotics Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "REWALK ROBOTICS  IS -,01",
    "state": null,
    "summary": "ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes wearable robotic exoskeletons for individuals with mobility impairments or other medical conditions in Israel, the United States, Europe, the Asia-Pacific, Latin America, and Africa. It offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for used in the rehabilitation of individuals with lower limb disability due to stroke; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers, institutions, and individuals, as well as through distributors. The company was formerly known as Argo Medical Technologies Ltd. and changed its name to ReWalk Robotics Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.",
    "website": "http://www.rewalk.com",
    "zipcode": "2069203"
  },
  "ALMD.TA": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Allmed Solutions Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ALLMED SOLUTIONS",
    "state": null,
    "summary": "Allium Medical Solutions Ltd., a medical device company, develops, manufactures, and markets minimally invasive products in Israel and internationally. The company offers covered stents, such as ureteral, round posterior, triangular prostatic, bulbar, and biliary stents. It also provides uro-gynecology products, including EndoFast Reliant Systems for reinforcement; EndoFast Resorb kits for fixation of surgical mesh to tissues for tissue reinforcement; EndoFast Reliant MN, an implantable, sub-urethral support sling for the treatment of male stress urinary incontinence; and EndoFast Reliant SCP for fixation of surgical mesh to tissue for tissue reinforcement during laparotomy or laparoscopic Sacrocolpopexy approach. In addition, the company offers gastro-duodenal sleeves for the treatment of diabetes mellitus and obesity; and WIRION EPD system, an embolic protection system. Allium Medical Solutions Ltd. is headquartered in Caesarea, Israel.",
    "website": "http://www.allium-medical.com",
    "zipcode": "3088900"
  },
  "APOP": {
    "city": "Kfar Saba",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Cellect Biotechnology Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Cellect Biotechnology Ltd.",
    "state": null,
    "summary": "Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische UniversitÃ¤t Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.",
    "website": "http://www.cellect.co",
    "zipcode": "44425"
  },
  "AYLA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Ayala Pharmaceuticals, Inc.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Ayala Pharmaceuticals, Inc.",
    "state": null,
    "summary": "Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.",
    "website": "http://www.ayalapharma.com",
    "zipcode": "7670104"
  },
  "BAV.F": {
    "city": "Hod HaSharon",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "BATM Advanced Communications Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BATM ADV. COMMCTNS IS-,01",
    "state": null,
    "summary": "BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.",
    "website": "http://www.batm.com",
    "zipcode": "4524075"
  },
  "BBIXF": {
    "city": "Haifa",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Bonus BioGroup Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BONUS BIOGROUP LTD",
    "state": null,
    "summary": "Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone trauma and arthritis. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.",
    "website": "http://www.bonusbiogroup.com",
    "zipcode": "31905"
  },
  "BIOV.TA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Bio-View Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "BIO VIEW",
    "state": null,
    "summary": "Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd was founded in 2000 and is headquartered in Rehovot, Israel.",
    "website": "http://www.bioview.com",
    "zipcode": "7670203"
  },
  "BIVWF": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Bio-View Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIO VIEW",
    "state": null,
    "summary": "Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd was founded in 2000 and is headquartered in Rehovot, Israel.",
    "website": "http://www.bioview.com",
    "zipcode": "7670203"
  },
  "BLRX": {
    "city": "Hevel Modi'in",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "BioLineRx Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BioLineRx Ltd.",
    "state": null,
    "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.",
    "website": "http://www.biolinerx.com",
    "zipcode": "7177871"
  },
  "BLRX.TA": {
    "city": "Hevel Modi'in",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "BioLineRx Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "BIOLINE RX LTD",
    "state": null,
    "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.",
    "website": "http://www.biolinerx.com",
    "zipcode": "7177871"
  },
  "BOLT.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "BioLight Life Sciences Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "BIOLIGHT LIFE SCI",
    "state": null,
    "summary": "BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. The company's ophthalmic product offering and pipeline of product candidates include IOPtiMate, a laser-based surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for dry eye syndrome; Eye-D, a controlled release drug-delivery insert platform; OphRx, a non-invasive topical drug delivery technology; and LipiTear, a micro-emulsion technology for the dry eye treatment, as well as for the treatment of other ocular diseases. It also invests in cancer diagnostics technologies, including proprietary tests that are designated for bladder, cervical, multiple myeloma, and other cancers. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel.",
    "website": "http://bio-light.co.il",
    "zipcode": "6158101"
  },
  "BRSYF": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "BrainsWay Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BRAINSWAY LTD",
    "state": null,
    "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
    "website": "http://www.brainsway.com",
    "zipcode": "9777518"
  },
  "BTAVF": {
    "city": "Hod HaSharon",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "BATM Advanced Communications Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BATM ADVANCED COMMUNICATIONS",
    "state": null,
    "summary": "BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.",
    "website": "http://www.batm.com",
    "zipcode": "4524075"
  },
  "BVC.L": {
    "city": "Hod HaSharon",
    "country": "Israel",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Medical Instruments & Supplies",
    "long_name": "BATM Advanced Communications Ltd.",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "BATM ADVANCED COMMUNICATIONS LD",
    "state": null,
    "summary": "BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.",
    "website": "http://www.batm.com",
    "zipcode": "4524075"
  },
  "BVXV": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "BiondVax Pharmaceuticals Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BiondVax Pharmaceuticals Ltd.",
    "state": null,
    "summary": "BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.",
    "website": "http://www.biondvax.com",
    "zipcode": "7414002"
  },
  "BWAY": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Medical Devices",
    "long_name": "BrainsWay Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Brainsway Ltd.",
    "state": null,
    "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
    "website": "http://www.brainsway.com",
    "zipcode": "9777518"
  },
  "BWAY.TA": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "BrainsWay Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "BRAINSWAY LTD",
    "state": null,
    "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
    "website": "http://www.brainsway.com",
    "zipcode": "9777518"
  },
  "CANF": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "USD",
    "exchange": "ASE",
    "industry": "Biotechnology",
    "long_name": "Can-Fite BioPharma Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Can-Fite Biopharma Ltd Sponsore",
    "state": null,
    "summary": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.",
    "website": "http://www.canfite.com",
    "zipcode": "4951778"
  },
  "CANF.TA": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Can-Fite BioPharma Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "CAN FITE BIOPHARMA",
    "state": null,
    "summary": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.",
    "website": "http://www.canfite.com",
    "zipcode": "4951778"
  },
  "CBI.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Clal Biotechnology Industries Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "CLAL BIOTECHNOLOGY",
    "state": null,
    "summary": "Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It invests between $0.5 million and $10 million per company. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel with an additional office in Cambridge, Massachusetts. It operates as a former subsidiary of Clal Industries and Investments Ltd.",
    "website": "http://www.cbi.co.il",
    "zipcode": "67023"
  },
  "CGEN": {
    "city": "Holon",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Compugen Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Compugen Ltd.",
    "state": null,
    "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
    "website": "http://www.cgen.com",
    "zipcode": "5885849"
  },
  "CGEN.TA": {
    "city": "Holon",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Compugen Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "COMPUGEN",
    "state": null,
    "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
    "website": "http://www.cgen.com",
    "zipcode": "5885849"
  },
  "CHEK": {
    "city": "Isfiya",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Diagnostics & Research",
    "long_name": "Check-Cap Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Check-Cap Ltd.",
    "state": null,
    "summary": "Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.",
    "website": "http://www.check-cap.com",
    "zipcode": "30090"
  },
  "CKNTF": {
    "city": "Lod",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Cell Kinetics Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CELL KINETICS LTD",
    "state": null,
    "summary": "Cell Kinetics Ltd. engages in the refining and commercialization of CellScan and related technology. It focuses on the development and commercialization of a cell carrier technology known as CKChip, a platform static cytometry technology that enables the simultaneous examination of various individual live cells using simple imaging methods, such as fluorescence microscopy. The company was founded in 1992 and is headquartered in Lod, Israel. Cell Kinetics Ltd. is a subsidiary of Medis Technologies Ltd.",
    "website": null,
    "zipcode": "71291"
  },
  "CLGN": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "CollPlant Biotechnologies Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CollPlant Biotechnologies Ltd.",
    "state": null,
    "summary": "CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",
    "website": "http://www.collplant.com",
    "zipcode": "7670104"
  },
  "CMMB": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Chemomab Therapeutics Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Chemomab Therapeutics Ltd.",
    "state": null,
    "summary": "Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.",
    "website": "http://www.chemomab.com",
    "zipcode": "6158002"
  },
  "CNMD.TA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Cannomed Medical Cannabis Industries LTD",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "CANNOMED MEDICAL",
    "state": null,
    "summary": "Cannomed Medical Cannabis Industries Ltd, a biopharmaceutical company, discovers and develops novel therapeutics. It focuses on discovering inhibitors for E3 ubiquitin ligases for the treatment of cancer, metabolic diseases, viral infection, and CNS related disorders. The company was founded in 1999 and is based in Rehovot, Israel.",
    "website": null,
    "zipcode": "76704"
  },
  "CNZN.TA": {
    "city": "Jaffa",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Canzon Israel Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "CANZON ISRAEL LTD",
    "state": null,
    "summary": "Canzon Israel Ltd manages and operates Internet sites in Israel. It offers various tools, such as forums, blogs, and video sharing platforms to users. The company also provides design and development services for Internet and mobile sectors. It serves corporations and large companies, technology product companies, and start-up customers. The company distributes its products through sales people, events, and cooperation agreements. The company was formerly known as User Trend Ltd. Canzon Israel Ltd was founded in 1999 and is based in Bnei Brak, Israel.",
    "website": null,
    "zipcode": "6249245"
  },
  "CPTA.F": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "CollPlant Biotechnologies Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "COLL.BIO. SP.ADR/1 -,01",
    "state": null,
    "summary": "CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",
    "website": "http://www.collplant.com",
    "zipcode": "7670104"
  },
  "CW9.F": {
    "city": "Holon",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Compugen Ltd.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "COMPUGEN LTD.",
    "state": null,
    "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
    "website": "http://www.cgen.com",
    "zipcode": "5885849"
  },
  "DANE.TA": {
    "city": "Ramat Gan",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Care Facilities",
    "long_name": "Danel (Adir Yeoshua) Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "DANEL-ADIR YEHOSHU",
    "state": null,
    "summary": "Danel (Adir Yeoshua) Ltd provides human resources services in Israel. It offers recruitment, placement, and employment services in the areas of employment, nursing, welfare, education, hi-tech, cleantech, biotech, finance, and others; and nursing services, such as nursing law services, private care in hospitals, private care by caregivers, assistance to holocaust survivors and foreign caregivers. The company also operates a social-rehabilitation day club, which provides social and recreational activities for the victims of hostile acts, as well as offers housing, education, employment, and other services. It serves government ministries, public bodies, the defense industries, and private companies. Danel (Adir Yeoshua) Ltd was founded in 1974 and is based in Ramat Gan, Israel.",
    "website": "http://www.danel-jobs.co.il",
    "zipcode": null
  },
  "DNA.TA": {
    "city": "Ramat Gan",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "D.N.A Biomedical Solutions Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "D.N.A BIOMEDICAL S",
    "state": null,
    "summary": "D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. The company offers remote scan systems for explosive detection; bottle liquid and powders, and hand held raman scanners that detects hazardous substances in liquids or powder forms; and luggage scanners for baggage screening. Its products are used in aviation and transportation security applications, such as baggage, personnel, and vehicle inspection; military applications; law enforcement and homeland security applications, including mega event security, multiple substances detection, and drug detection, as well as identification of solids, gases, and liquids in transparent containers; and monitoring and detection of hazardous materials in emergency situations. The company was formerly known as Laser Detect Systems Ltd. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel.",
    "website": "http://www.laser-detect.com",
    "zipcode": "5250607"
  },
  "EFNC.TA": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Erech Finance Cahalacha Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ERECH FINANCE",
    "state": null,
    "summary": "Erech Finance Cahalacha Ltd operates as a medical equipment company. It provides therapeutic medical devices for diabetes. The company is based in Jerusalem, Israel.",
    "website": null,
    "zipcode": "9123101"
  },
  "EMITF": {
    "city": "Petach Tikva",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Elbit Imaging Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELBIT IMAGING LTD",
    "state": null,
    "summary": "Elbit Imaging Ltd., together with its subsidiaries, engages in research and development, production, and marketing of treatment-oriented medical systems; and products to treat cancer diseases. Its treatment-oriented medical systems include magnetic resonance imaging for the purpose of performing noninvasive treatments in human beings. The company is also involved in the sale of plots in India. It has operations in the United States, Europe, and internationally. The company was founded in 1996 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.elbitimaging.com",
    "zipcode": "4952801"
  },
  "EMITF.TA": {
    "city": "Petach Tikva",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Elbit Imaging Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ELBIT IMAGING LTD",
    "state": null,
    "summary": "Elbit Imaging Ltd., together with its subsidiaries, engages in research and development, production, and marketing of treatment-oriented medical systems; and products to treat cancer diseases. Its treatment-oriented medical systems include magnetic resonance imaging for the purpose of performing noninvasive treatments in human beings. The company is also involved in the sale of plots in India. It has operations in the United States, Europe, and internationally. The company was founded in 1996 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.elbitimaging.com",
    "zipcode": "4952801"
  },
  "EMTC.TA": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Elbit Medical Technologies Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ELBIT MEDICAL TECH",
    "state": null,
    "summary": "Elbit Medical Technologies Ltd, an investment holding company, engages in the research, development, production, and marketing of magnetic and focused imaging equipment in the United States, Europe, and internationally. The company is developing a magnetic resonance imaging guided focused ultrasound treatment equipment to address various oncology and gynecology indications, as well as neurological disorders and tumors. It is also involved in the study and development of medical products based on stem cells originating primarily from the umbilical cord blood that are used for bone marrow transplants in the patients of leukemia or cancer of lymph nodes, non-malignant blood diseases, and metabolic genetic disorders. The company is based in Petah Tikva, Israel. Elbit Medical Technologies Ltd is a subsidiary of Elbit Imaging Ltd.",
    "website": null,
    "zipcode": "4900102"
  },
  "ENLV": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Enlivex Therapeutics Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Enlivex Therapeutics Ltd.",
    "state": null,
    "summary": "Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",
    "website": "http://www.enlivex.com",
    "zipcode": "7403618"
  },
  "ENLV.TA": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Enlivex Therapeutics Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ENLIVEX THERAPEUTI",
    "state": null,
    "summary": "Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",
    "website": "http://www.enlivex.com",
    "zipcode": "7403618"
  },
  "ENTX": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Entera Bio Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Entera Bio Ltd.",
    "state": null,
    "summary": "Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",
    "website": "http://www.enterabio.com",
    "zipcode": "9122002"
  },
  "EVGN": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Evogene Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Evogene Ltd.",
    "state": null,
    "summary": "Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",
    "website": "http://www.evogene.com",
    "zipcode": "7414002"
  },
  "EVGN.TA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Evogene Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "EVOGENE LTD",
    "state": null,
    "summary": "Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",
    "website": "http://www.evogene.com",
    "zipcode": "7414002"
  },
  "GLMD": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Galmed Pharmaceuticals Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Galmed Pharmaceuticals Ltd.",
    "state": null,
    "summary": "Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.galmedpharma.com",
    "zipcode": "6578317"
  },
  "GMDA": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Gamida Cell Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Gamida Cell Ltd.",
    "state": null,
    "summary": "Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",
    "website": "http://www.gamida-cell.com",
    "zipcode": "91340"
  },
  "GMMVF": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "G Medical Innovations Holdings Ltd",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "G MEDICAL INNOVATIONS HLDGS LTD",
    "state": null,
    "summary": "G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. G Medical Innovations Holdings Ltd was founded in 2014 and is based in Rehovot, Israel.",
    "website": "http://gmedinnovations.com",
    "zipcode": "7670105"
  },
  "GOHO.TA": {
    "city": "Tel-Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Care Facilities",
    "long_name": "Golden House Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "GOLDEN HOUSE",
    "state": null,
    "summary": "Golden House Ltd provides assisted independent living services for elderly population in Israel. It operates The Golden Age House TA, an assisted independent living house that contains 300 housing units, as well as public spaces, including a lobby, club, restaurant, coffee shop, library, movie theatre, synagogue, classroom, lecture room, fitness center, spa, and green garden terrace. The company also offers nursing care services. Golden House Ltd was founded in 1982 and is based in Tel-Aviv, Israel.",
    "website": "http://www.golden-house.co.il",
    "zipcode": "67320"
  },
  "H2K2.F": {
    "city": "Ramat Gan",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "XTL Biopharmaceuticals Ltd.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "XTL BIOPHARMA. ADR 100",
    "state": null,
    "summary": "XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.",
    "website": "http://www.xtlbio.com",
    "zipcode": "5218102"
  },
  "HDST.TA": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Hadasit Bio-Holdings Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "HBL-HADASIT BIO",
    "state": null,
    "summary": "Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.",
    "website": "http://www.hbl.co.il",
    "zipcode": "91120"
  },
  "HSITF": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Hadasit Bio-Holdings Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HBL - HADASIT BIO HOLDINGS LTD",
    "state": null,
    "summary": "Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.",
    "website": "http://www.hbl.co.il",
    "zipcode": "91120"
  },
  "HUMX.TA": {
    "city": "Netanya",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Human Xtensions Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "HUMAN XTENSIONS LT",
    "state": null,
    "summary": "Human Xtensions Ltd. develops unmediated surgical systems. It offers HandX, a handheld medical device for use in laparoscopic procedures. The company was founded in 2012 and is based in Netanya, Israel.",
    "website": "http://human-x.com",
    "zipcode": "4250574"
  },
  "ICB.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Israel China Biotechnology (ICB) Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ICB BIOTECHNOLOGY",
    "state": null,
    "summary": "Israel China Biotechnology (ICB) Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was founded in 2000 and is based in Tel Aviv, Israel.",
    "website": "http://www.icbinvest.co",
    "zipcode": "6971918"
  },
  "ICCM.TA": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Care Facilities",
    "long_name": "IceCure Medical Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ICECURE MEDICAL LT",
    "state": null,
    "summary": "IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.",
    "website": "http://www.icecure-medical.com",
    "zipcode": "3079504"
  },
  "ICUSF": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "IceCure Medical Ltd",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ICECURE MEDICAL LTD",
    "state": null,
    "summary": "IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.",
    "website": "http://www.icecure-medical.com",
    "zipcode": "3079504"
  },
  "IDTA": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "IDenta Corp.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IDENTA CORP",
    "state": null,
    "summary": "IDenta Corp. develops, manufactures, and supplies field detection and home diagnostics testing kits for narcotics and explosives, and forensic products in the homeland security and consumer markets worldwide. The company offers drug, explosives, and bullet-hole testing kits; FerroPrint testing products; blood detection kits; precursors of drugs test kits; and portable sniffers. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. IDenta Corp. is headquartered in Jerusalem, Israel.",
    "website": "http://www.identa-corp.com",
    "zipcode": "93420"
  },
  "IGAP": {
    "city": "Ashdod",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Integrity Applications, Inc.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INTEGRITY APPLICATIONS INCORPOR",
    "state": null,
    "summary": "Integrity Applications, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe and the Asia Pacific. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was founded in 2001 and is based in Ashdod, Israel.",
    "website": "http://www.integrity-app.com",
    "zipcode": "7760049"
  },
  "II2.F": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "InspireMD, Inc.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INSPIREMD 1/18 DL-,0001",
    "state": null,
    "summary": "InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.inspiremd.com",
    "zipcode": "6744832"
  },
  "IMCC": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "IM Cannabis Corp.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IM Cannabis Corp.",
    "state": null,
    "summary": "IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.",
    "website": "http://www.imcannabis.com",
    "zipcode": null
  },
  "IMCC.CN": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "CAD",
    "exchange": "CNQ",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "IM Cannabis Corp.",
    "market": "ca_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMCannabisCorp",
    "state": null,
    "summary": "IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.",
    "website": "http://www.imcannabis.com",
    "zipcode": null
  },
  "IMED-L.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Health Information Services",
    "long_name": "I.I.M. Infinity Innonation Medical - Limited Partnership",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "IMED INFINITY MEDICAL LTD PARTN",
    "state": null,
    "summary": "I.I.M. Infinity Innonation Medical - Limited Partnership, a research and development partnership, focuses on investing in research projects and development in the medical field, primarily the health field. The company was incorporated in 2020 and is based in Tel Aviv, Israel.",
    "website": null,
    "zipcode": "6701101"
  },
  "INCR-U.TO": {
    "city": "Herzliya",
    "country": "Israel",
    "currency": "USD",
    "exchange": "TOR",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "InterCure Ltd.",
    "market": "ca_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INTERCURE LTD USD",
    "state": null,
    "summary": "InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.",
    "website": "http://www.intercure.co",
    "zipcode": "4676670"
  },
  "INCR.TA": {
    "city": "Herzliya",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "InterCure Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "INTERCURE LTD",
    "state": null,
    "summary": "InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.",
    "website": "http://www.intercure.co",
    "zipcode": "4676670"
  },
  "INMD": {
    "city": "Yokne'am",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Medical Devices",
    "long_name": "InMode Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "InMode Ltd.",
    "state": null,
    "summary": "InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.",
    "website": "http://www.inmodemd.com",
    "zipcode": "2069206"
  },
  "INTL.TA": {
    "city": "Beit Dagan",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Intelicanna Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "INTELICANNA LTD",
    "state": null,
    "summary": "Intelicanna Ltd provides various management consulting services in Israel, the United States, Europe, and internationally. The company offers its services in the areas of corporate strategy, global strategy, marketing strategy, mergers and acquisitions, turnaround management, and innovation strategy; and sales and marketing areas, such as sales and channel management, customer relationship management, customer lifecycle, organization and capabilities, product launch, sales force efficiency, and pricing. It also provides operation and organization services in various areas comprising operational excellence, customer service, organization design, change management, and people capabilities; and services in the areas of manufacturing and quality, including quality management, lean manufacturing, six sigma, capacity planning and OEE, and facility design. In addition, the company offers services in the areas of supply chain comprising strategy and risk management, planning, procurement, distribution and logistics, and reverse logistics and green supply chain; and portfolio management, project management excellence, IT governance, risk management, and design for X methodology. Further, it provides services in the areas of corporate finance, such as financial reporting and cost controlling, financing strategy and financial control, value based management, and financial restructuring services. Additionally, the company offers Tefen AI, an artificial intelligence tool for businesses. It serves various companies in the retail, patient care, life sciences, healthcare, financial services, general manufacturing, aviation and transportation, consumer goods, telecommunications, energy and utilities, public sector, high tech, semiconductors, and legal industries. The company was formerly known as Tefen Industrial Engineering & Management & Systems Analysis and changed its name to Intelicanna Ltd. Intelicanna Ltd was founded in 1982 and is based in Beit-Dagan, Israel.",
    "website": "http://www.tefen.com",
    "zipcode": "50200"
  },
  "IRCLF": {
    "city": "Herzliya",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "InterCure Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INTERCURE LTD",
    "state": null,
    "summary": "InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.",
    "website": "http://www.intercure.co",
    "zipcode": "4676670"
  },
  "IRME": {
    "city": "Rosh Pina",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "IR-Med Inc.",
    "market": "us_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "IR-MED INC",
    "state": null,
    "summary": "IR-Med Inc., a medical device company, focuses on the development of infra-red light spectroscopy (IR) and artificial intelligence (AI) combined technology solutions to address the diagnosis of medical ailments. It develops PressureSafe, a non-invasive and real-time optical monitoring device for the preemptive detection of pressure injury; and Nobiotics, an advanced otoscope that works on IR-spectrographic analysis technology providing doctors an immediate indication of the infection being viral or bacterial. The company also engages in developing a real-time noninvasive optical monitor to determine Propofol blood concentration. Its products are used for applications in pressure injury, ear inflammation, and other pharmaceutical areas. IR-Med Inc. is headquartered in Rosh Pina, Israel.",
    "website": "http://www.ir-medical.com",
    "zipcode": "1210002"
  },
  "ITMMF": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Itamar Medical Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ITAMAR MEDICAL LTD",
    "state": null,
    "summary": "Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel.",
    "website": "http://www.itamar-medical.com",
    "zipcode": "3079883"
  },
  "ITMR": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Medical Devices",
    "long_name": "Itamar Medical Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Itamar Medical Ltd. - American ",
    "state": null,
    "summary": "Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel.",
    "website": "http://www.itamar-medical.com",
    "zipcode": "3079883"
  },
  "ITMR.TA": {
    "city": "Caesarea",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Devices",
    "long_name": "Itamar Medical Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "ITAMAR MEDICAL LTD",
    "state": null,
    "summary": "Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel.",
    "website": "http://www.itamar-medical.com",
    "zipcode": "3079883"
  },
  "KDST.TA": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Kadimastem Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "KADIMASTEM",
    "state": null,
    "summary": "Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.",
    "website": "http://www.kadimastem.com",
    "zipcode": "74140"
  },
  "KMDA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kamada Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Kamada Ltd.",
    "state": null,
    "summary": "Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.",
    "website": "http://www.kamada.com",
    "zipcode": "7670402"
  },
  "KMDA.TA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Kamada Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "KAMADA LTD",
    "state": null,
    "summary": "Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.",
    "website": "http://www.kamada.com",
    "zipcode": "7670402"
  },
  "KMSTF": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Kadimastem Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KADIMASTEM LTD",
    "state": null,
    "summary": "Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.",
    "website": "http://www.kadimastem.com",
    "zipcode": "74140"
  },
  "M8W.F": {
    "city": "Yavne",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "MediWound Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIWOUND LTD  IS-,01",
    "state": null,
    "summary": "MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",
    "website": "http://www.mediwound.com",
    "zipcode": "8122745"
  },
  "MDGS": {
    "city": "Omer",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Medical Devices",
    "long_name": "Medigus Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Medigus Ltd.",
    "state": null,
    "summary": "Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel.",
    "website": "http://www.medigus.com",
    "zipcode": "8496500"
  },
  "MDWD": {
    "city": "Yavne",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "MediWound Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MediWound Ltd.",
    "state": null,
    "summary": "MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",
    "website": "http://www.mediwound.com",
    "zipcode": "8122745"
  },
  "MRHL.TA": {
    "city": "Bnei Brak",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Care Facilities",
    "long_name": "Merchavia Holdings and Investments Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "MERCHAVIA HOLD",
    "state": null,
    "summary": "Merchavia Holdings and Investments Ltd. invests in life science companies in Israel. It has a strategic partnership with Cleveland clinic in the United States. The company was formerly known as Nepco Star Ltd. and changed its name to Merchavia Holdings and Investments Ltd. in November 2014. Merchavia Holdings and Investments Ltd. was founded in 1972 and is headquartered in Bnei Brak, Israel.",
    "website": "http://merchavia.com",
    "zipcode": "5126112"
  },
  "NISA.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nissan Medical Industries Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "NISSAN",
    "state": null,
    "summary": "Nissan Medical Industries Ltd., through its subsidiary, produces and sells spun lace non-woven fabrics in the United States, Canada, Europe, and Israel. Its products are used in wipes, medical products, automotive, and hygienic industries. The company sells its products through its sales agents. Nissan Medical Industries Ltd. was founded in 1984 and is based in Tel Aviv, Israel.",
    "website": null,
    "zipcode": "6971411"
  },
  "NNOX": {
    "city": "Neve Ilan",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Medical Devices",
    "long_name": "Nano-X Imaging Ltd.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANO-X IMAGING LTD",
    "state": null,
    "summary": "Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel digital MEMs semiconductor cathode. The company also develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Neve Ilan, Israel.",
    "website": "http://www.nanox.vision",
    "zipcode": "9085000"
  },
  "NSPR": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "ASE",
    "industry": "Medical Devices",
    "long_name": "InspireMD, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "InspireMD Inc.",
    "state": null,
    "summary": "InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.inspiremd.com",
    "zipcode": "6744832"
  },
  "NTEC": {
    "city": "Jerusalem",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Intec Pharma Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Intec Pharma Ltd.",
    "state": null,
    "summary": "Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was incorporated in 2000 and is based in Jerusalem, Israel.",
    "website": "http://www.intecpharma.com",
    "zipcode": "9777512"
  },
  "NVLG.TA": {
    "city": "Modi'in-Maccabim-Re'ut",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Care Facilities",
    "long_name": "Novolog (Pharm-Up 1966) Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "NOVOLOG",
    "state": null,
    "summary": "Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.",
    "website": "http://www.novolog.co.il",
    "zipcode": "717131"
  },
  "NXGN.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nextgen Biomed Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "NEXTGEN BIOMED LTD",
    "state": null,
    "summary": "Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.",
    "website": "http://www.nextgen-biomed.com",
    "zipcode": "6701101"
  },
  "NXTG.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nextage Therapeutics Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "NEXTAGE THERAPEUTI",
    "state": null,
    "summary": "Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomarker and histochemical assays for early cancer detection and personalized medicine. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. The company was formerly known as Micromedic Technologies Ltd and changed its name to Nextage Therapeutics Ltd in August 2020. Nextage Therapeutics Ltd is based in Tel Aviv, Israel.",
    "website": "http://www.m-medic.com",
    "zipcode": "6158101"
  },
  "OWCP": {
    "city": "Ramat Gan",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "OWC Pharmaceutical Research Corp.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OWC PHARMACEUTICAL RESEARCH COR",
    "state": null,
    "summary": "OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. It develops cannabis-based medical products for the treatment of various conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia. The company is also involved in developing cannabis soluble tablet delivery system. In addition, it provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations. The company was formerly known as Dynamic Applications Corp. and changed its name to OWC Pharmaceutical Research Corp. in December 2014. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Ramat Gan, Israel.",
    "website": "http://www.owcpharma.com",
    "zipcode": "5257334"
  },
  "PBDA.F": {
    "city": "Karmiel",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Protalix BioTherapeutics, Inc.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PROTALIX BIOTHERAP.DL-,01",
    "state": null,
    "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃ§Ã£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
    "website": "http://www.protalix.com",
    "zipcode": "2161401"
  },
  "PHGE": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "USD",
    "exchange": "ASE",
    "industry": "Biotechnology",
    "long_name": "BiomX Inc.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BiomX Inc.",
    "state": null,
    "summary": "BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",
    "website": "http://www.biomx.com",
    "zipcode": "7414002"
  },
  "PHGE.TA": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "BiomX Inc.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "BIOMX INC",
    "state": null,
    "summary": "BiomX Inc., a clinical stage company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",
    "website": "http://www.biomx.com",
    "zipcode": "7414002"
  },
  "PJT.F": {
    "city": "Haifa",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pluristem Therapeutics Inc.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PLURISTEM THERAPEUTICS",
    "state": null,
    "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
    "website": "http://www.pluristem.com",
    "zipcode": "31905"
  },
  "PLNT.TA": {
    "city": "Ra'anana",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "PlantArc Bio Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PLANTARC BIO LTD",
    "state": null,
    "summary": "PlantArc Bio Ltd. operates as a biotechnology company for the enhancement of crop productivity and performance for food security. The company has developed a Direct In Plant gene discovery platform. It focuses on yield and abiotic stresses, insect resistance, herbicide tolerance, and disease control market segments. The company was founded in 2014 and is based in Ra'anana, Israel.",
    "website": "http://plantarcbio.com",
    "zipcode": "4390500"
  },
  "PLX": {
    "city": "Karmiel",
    "country": "Israel",
    "currency": "USD",
    "exchange": "ASE",
    "industry": "Biotechnology",
    "long_name": "Protalix BioTherapeutics, Inc.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Protalix BioTherapeutics, Inc. ",
    "state": null,
    "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃ§Ã£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
    "website": "http://www.protalix.com",
    "zipcode": "2161401"
  },
  "PLX.TA": {
    "city": "Karmiel",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Protalix BioTherapeutics, Inc.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PROTALIX BIOTHERAP",
    "state": null,
    "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃ§Ã£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
    "website": "http://www.protalix.com",
    "zipcode": "2161401"
  },
  "PMCN.TA": {
    "city": "Raanana",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Pharmocann Global Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PHARMOCANN GLOBAL",
    "state": null,
    "summary": "Pharmocann Global Ltd engages in cultivation of cannabis for medical purposes. The company was founded in 2008 and is based in Raanana, Israel.",
    "website": "http://pharmocann.com",
    "zipcode": "4335810"
  },
  "PNAX.TA": {
    "city": "Lod",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Panaxia Labs Israel Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PANAXIA LABS ISRAE",
    "state": null,
    "summary": "Panaxia Pharmaceutical Industries Ltd provides pharmaceutical solutions for patients and physicians. The company offers pharma-grade smokeless cannabis products, such as oral and sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches. Panaxia Pharmaceutical Industries Ltd has strategic partnerships with Ultra Health, Salus Biopharma, MPX Bioceutical Corporation, Rafa, Pharmocann, Seach Medical Cannabis Group, TevaAdir, Better, and Cann10. The company was incorporated in 2016 and is based in Lod, Israel.",
    "website": "http://www.panaxia.co.il",
    "zipcode": "7116002"
  },
  "PPBT": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Purple Biotech Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Purple Biotech Ltd.",
    "state": null,
    "summary": "Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.",
    "website": "http://purple-biotech.com",
    "zipcode": "7670104"
  },
  "PPBT.TA": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Purple Biotech Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PURPLE BIOTECH",
    "state": null,
    "summary": "Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.",
    "website": "http://purple-biotech.com",
    "zipcode": "7670104"
  },
  "PRFX": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "PainReform Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PainReform Ltd.",
    "state": null,
    "summary": "PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.",
    "website": "http://www.painreform.com",
    "zipcode": "6745442"
  },
  "PSTI": {
    "city": "Haifa",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Pluristem Therapeutics Inc.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Pluristem Therapeutics, Inc.",
    "state": null,
    "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
    "website": "http://www.pluristem.com",
    "zipcode": "31905"
  },
  "PSTI.TA": {
    "city": "Haifa",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Pluristem Therapeutics Inc.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "PLURISTEM THERAPEU",
    "state": null,
    "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
    "website": "http://www.pluristem.com",
    "zipcode": "31905"
  },
  "PYPD": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "PolyPid Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PolyPid Ltd.",
    "state": null,
    "summary": "PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.",
    "website": "http://www.polypid.com",
    "zipcode": "4959376"
  },
  "RDHL": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "RedHill Biopharma Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Redhill Biopharma Ltd.",
    "state": null,
    "summary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.redhillbio.com",
    "zipcode": "6473921"
  },
  "REKA.TA": {
    "city": "Holon",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Rekah Pharmaceutical Industry Ltd.",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "REKAH PHARMA IND",
    "state": null,
    "summary": "Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; dermatological preparations; baby products; and vitamins and nutritional supplements. Its portfolio of products comprise approximately 280 drugs used in various medical fields. The company was founded in 1941 and is based in Holon, Israel.",
    "website": "http://www.rekah.co.il",
    "zipcode": "5881904"
  },
  "ROSGQ": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Rosetta Genomics Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ROSETTA GENOMICS LTD",
    "state": null,
    "summary": "Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.",
    "website": "http://www.rosettagenomics.com",
    "zipcode": "76706"
  },
  "RWLK": {
    "city": "Yokneam Illit",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Medical Devices",
    "long_name": "ReWalk Robotics Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ReWalk Robotics Ltd.",
    "state": null,
    "summary": "ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes wearable robotic exoskeletons for individuals with mobility impairments or other medical conditions in Israel, the United States, Europe, the Asia-Pacific, Latin America, and Africa. It offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for used in the rehabilitation of individuals with lower limb disability due to stroke; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers, institutions, and individuals, as well as through distributors. The company was formerly known as Argo Medical Technologies Ltd. and changed its name to ReWalk Robotics Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.",
    "website": "http://www.rewalk.com",
    "zipcode": "2069203"
  },
  "SHLTN.SW": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Health Information Services",
    "long_name": "SHL Telemedicine Ltd.",
    "market": "ch_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SHL TELEMEDICINE N",
    "state": null,
    "summary": "SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.shl-telemedicine.com",
    "zipcode": "67891"
  },
  "SLGL": {
    "city": "Ness Ziona",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Sol-Gel Technologies Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Sol-Gel Technologies Ltd.",
    "state": null,
    "summary": "Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.",
    "website": "http://www.sol-gel.com",
    "zipcode": "7403650"
  },
  "SLGN.TA": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Biotechnology",
    "long_name": "Solegreen Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "SOLEGREEN LTD",
    "state": null,
    "summary": "Solegreen Ltd engages in the renewable energy business in Israel. It operates and maintains solar energy facilities. The company was formerly known as Procognia (Israel) Ltd. and changed its name to Solegreen Ltd in January 2015. Solegreen Ltd was founded in 2000 and is based in Herzliya, Israel. As per the transaction announced on September 3, 2018, Solegreen Ltd operates as a subsidiary of Lahav Green Mountains Ltd.",
    "website": "http://solegreen.co.il",
    "zipcode": "6165202"
  },
  "SPRCY": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "SciSparc Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SCISPARC LTD",
    "state": null,
    "summary": "SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.",
    "website": "http://scisparc.com",
    "zipcode": "6971916"
  },
  "SZO.F": {
    "city": "Tel Aviv",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "SHL Telemedicine Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SHL TELEMEDICINE  IS-,01",
    "state": null,
    "summary": "SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.",
    "website": "http://www.shl-telemedicine.com",
    "zipcode": "67891"
  },
  "TAL.F": {
    "city": "Haifa",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Taro Pharmaceutical Industries Ltd.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "TARO PHAR.INDS. IS 0,0001",
    "state": null,
    "summary": "Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.",
    "website": "http://www.taro.com",
    "zipcode": "2624761"
  },
  "TARO": {
    "city": "Haifa",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Taro Pharmaceutical Industries Ltd.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Taro Pharmaceutical Industries ",
    "state": null,
    "summary": "Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.",
    "website": "http://www.taro.com",
    "zipcode": "2624761"
  },
  "TEV.F": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Teva Pharmaceutical Industries Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TEVA PHARMACEUT. SP.ADR",
    "state": null,
    "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.tevapharm.com",
    "zipcode": "4951033"
  },
  "TEVA": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Teva Pharmaceutical Industries Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Teva Pharmaceutical Industries ",
    "state": null,
    "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.tevapharm.com",
    "zipcode": "4951033"
  },
  "TEVA.TA": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Teva Pharmaceutical Industries Limited",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "TEVA PHARMA IND",
    "state": null,
    "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.tevapharm.com",
    "zipcode": "4951033"
  },
  "TEVA.VI": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Teva Pharmaceutical Industries Limited",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TEVA PHARMACEUTICAL ADR",
    "state": null,
    "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.tevapharm.com",
    "zipcode": "4951033"
  },
  "TEVAN.MX": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Drugs - Generic",
    "long_name": "Teva Pharmaceutical Industries Limited",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TEVA PHARMACEUTICAL INDUSTRIES",
    "state": null,
    "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.tevapharm.com",
    "zipcode": "4951033"
  },
  "TEVJF": {
    "city": "Petah Tikva",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Teva Pharmaceutical Industries Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "TEVA PHARMACEUTICAL INDUSTRIES",
    "state": null,
    "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.",
    "website": "http://www.tevapharm.com",
    "zipcode": "4951033"
  },
  "TGTR.TA": {
    "city": "Ashkelon",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Together Pharma Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "TOGETHER PHARMA",
    "state": null,
    "summary": "Together Pharma Ltd, through its subsidiaries, engages in growing, production, storage, and distribution of medical cannabis products in Israel. The company is based in Ashkelon, Israel.",
    "website": "http://www.together-pharma.com",
    "zipcode": "7810001"
  },
  "TKUN.TA": {
    "city": "Tel Aviv-Yafo",
    "country": "Israel",
    "currency": "ILA",
    "exchange": "TLV",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Tikun Olam - Cannbit Pharmaceuticals Ltd",
    "market": "il_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "TIKUN OLAM - CANNB",
    "state": null,
    "summary": "Tikun Olam - Cannbit Pharmaceuticals Ltd engages in the research, development, cultivation, manufacture, marketing, and sale of medical cannabis and related products. The company was incorporated in 1995 and is based in Tel Aviv-Yafo, Israel.",
    "website": "http://tikun-olam.org.il",
    "zipcode": null
  },
  "TOMDF": {
    "city": "Rehovot",
    "country": "Israel",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Todos Medical Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TODOS MEDICAL LIMITED",
    "state": null,
    "summary": "Todos Medical Ltd., a clinical-stage medical diagnostics company, develops and commercializes blood tests for the detection of immune-related diseases in Israel and internationally. The company develops Total Biochemical Infrared Analysis method, a proprietary method for screening of solid tumors using peripheral blood spectroscopy analysis; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis product includes TM-B1 and TM-B2 for breast cancer blood tests; and TM-C1 for testing of colorectal cancer. The company also imports and distributes personal protective equipment, test kits, and medical devices, such as ventilators. Todos Medical Ltd. has partnership with Moto-Para and Meridian HSN to provide a complete turnkey solution for on-site COVID testing. Todos Medical Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.",
    "website": "http://todosmedical.com",
    "zipcode": "7670301"
  },
  "VBLT": {
    "city": "Hevel Modi'in",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Vascular Biogenics Ltd.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Vascular Biogenics Ltd.",
    "state": null,
    "summary": "Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.",
    "website": "http://www.vblrx.com",
    "zipcode": "7178106"
  },
  "XTLB": {
    "city": "Ramat Gan",
    "country": "Israel",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "XTL Biopharmaceuticals Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "XTL Biopharmaceuticals Ltd.",
    "state": null,
    "summary": "XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.",
    "website": "http://www.xtlbio.com",
    "zipcode": "5218102"
  },
  "YP2A.F": {
    "city": "Hevel Modi'in",
    "country": "Israel",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BioLineRx Ltd.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOLIN.RX S.ADR 15 IL-,01",
    "state": null,
    "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.",
    "website": "http://www.biolinerx.com",
    "zipcode": "7177871"
  }
}
